Verici Dx plc

Company Profile

Company website
Health Care/Medical Equipment and Services (Medical Services)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Investor Access

22 Nov
Event information

The CEO will be providing a live presentation relating to the Company’s recent global licensing and commercialisation agreement for its pre-transplant test (Clarava™) with Thermo Fisher Scientific via the Investor Meet Company platform on 22 November 2023

Investors can sign up to Investor Meet Company for free and add to meet Verici Dx plc via the following link:
Wednesday 22 November 2023 at 5pm (GMT)
Financial Calendar
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*June
Interim Results*September

* Months based on previous announcements of this kind